How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

100 results for

Symlin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Symlin

Symlin Symlin Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Symlin Symlin Aka: Symlin , Pramlintide , Amylinomimetic , Amylin (...) efficacy are preferred) Expensive (>$1000) X. Efficacy Drops A1C 0.5 to 0.6% (contrast with : 0.25% ) XI. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Symlin." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Cost: Medications symlin (on 1/1/2017 at ) SYMLINPEN 120 PEN INJECTOR $172.13 per ml SYMLINPEN 60 PEN INJECTOR $261.39 per ml FPNotebook

2018 FP Notebook

2. Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery

Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01841359 Recruitment Status : Unknown Verified April 2017 by Joslin Diabetes Center. Recruitment status was: Active, not recruiting First Posted

2013 Clinical Trials

3. Symlin

Symlin Symlin Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Symlin Symlin Aka: Symlin , Pramlintide , Amylinomimetic , Amylin (...) efficacy are preferred) Expensive (>$1000) X. Efficacy Drops A1C 0.5 to 0.6% (contrast with : 0.25% ) XI. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Symlin." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Cost: Medications symlin (on 1/1/2017 at ) SYMLINPEN 120 PEN INJECTOR $172.13 per ml SYMLINPEN 60 PEN INJECTOR $261.39 per ml FPNotebook

2015 FP Notebook

4. Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus

Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy Study (...) of High Dose Symlin to Treat Type 2 Diabetes Mellitus The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01137695 Recruitment Status : Unknown Verified October 2011 by Cheryl Rosenfeld, DO, North Jersey Endocrine Consultants, LLC. Recruitment status was: Active, not recruiting First Posted : June 4, 2010

2010 Clinical Trials

5. The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes

The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes (T2DM) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00950677 Recruitment Status : Completed First Posted : August 3, 2009 Last Update Posted : April

2009 Clinical Trials

6. Exenatide (Byetta) Versus Pramlintide (Symlin): Role in Post-Prandial Hyperglycemia

Exenatide (Byetta) Versus Pramlintide (Symlin): Role in Post-Prandial Hyperglycemia Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) : Exenatide Drug: Insulin Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 37 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Exenatide (Byetta) Vs Pramlintide (Symlin): Role in Post-prandial Hyperglycemia Study Start Date : August 2009 Actual Primary Completion Date : August 2016 Actual Study Completion Date : December 2016

2009 Clinical Trials

7. Diabetes Type 1

significant benefit except in specific situations, such as patients who have well documented frequent and/or severe hypoglycemia despite best-practice management. For more information, see Clinical Review Criteria: Continuous Glucose Monitor. Pharmacologic options that are not recommended The following pharmacologic options are not recommended or not on the formulary; consider consultation with the Diabetes Team. ? Amylinomimetics—pramlintide (Symlin) ? Insulin analogs—insulin detemir (Levemir) (PA

2017 Kaiser Permanente Clinical Guidelines

8. Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes?

Diabetes Canada, have acknowledged that there may be a role for adjunctive therapy in some T1D patients. 10,23,40 In the US, pramlintide acetate injection (Symlin) is the only noninsulin drug approved for adjunctive treatment of T1D. 13,29 Metformin, a T2D medication, is mentioned by Diabetes Canada and the American Diabetes Association for off-label use to reduce insulin requirements and total cholesterol/low-density lipoprotein ratios, 10,17,23 with the caveat that it does not improve hemoglobin A1C

2018 CADTH - Issues in Emerging Health Technologies

9. Management of Type 2 Diabetes Mellitus

for patients with type 2 diabetes. However, their use is rarely successful in patients with type 1 diabetes. 21 UMHS Management of Type 2 Diabetes Mellitus June, 2017 Symlin. Symlin is not a type of insulin but an amylinomimetic agent approved as adjunct therapy in patients with type 1 and type 2 diabetes who use mealtime insulin but who are not achieving optimal control. Symlin is used at mealtimes to augment the effects of insulin on glycemic control. This can cause hypoglycemia which can occur within 3 (...) hours after a symlin injection. Symlin and insulin should never be mixed in the same syringe. Symlin can also suppress appetite and lead to weight loss. Nausea is the most common side effect but improves with time in most patients. Co-Morbid Conditions Hypertension. Hypertension (HTN) is the predominant predictor of adverse events in patients with type 2 diabetes. Treatment of blood pressure reduces risks of major cardiovascular events such as myocardial infarction, stroke, or cardiovascular death

2017 University of Michigan Health System

10. The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas

and is capable of adhering to the protocol. Willingness to switch to lispro (Humalog) or aspart (Novolog) if not using already, and to use no other insulin besides lispro (Humalog) or aspart (Novolog) during the study. Total daily insulin dose (TDD) at least 10 U/day. Willingness not to start any new non-insulin glucose-lowering agent during the course of the trial. Exclusion Criteria Concurrent use of any non-insulin glucose-lowering agent other than metformin (including GLP-1 agonists, Symlin, DPP-4

2018 Clinical Trials

11. Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease

will have a final check of vital signs and blood glucose approximately 15 min before discharge. Other Name: Symlin Active Comparator: Amnestic MCI Participants with amnestic MCI with or without positive AD imaging pathology will receive the pramlintide challenge test. Drug: Pramlintide challenge test Enrolled subjects will have a pre-trial blood draw (3 ml) and will be placed with an IV needle for future blood draws. Pramlintide will be subcutaneously injected in the abdominal area. For each arm (...) the participants will be randomized so that half will be given a dose of 0.8 mcg/kg and the other half of the arm a dose of 1.6 mcg/kg. Blood will be drawn before and at 5, 30, 60, and 180 min after injection. Vital signs and blood glucose will also be checked at these time points. Thirty minutes after the injection, subjects will be offered a standard meal. Subjects will have a final check of vital signs and blood glucose approximately 15 min before discharge. Other Name: Symlin Active Comparator: Control

2018 Clinical Trials

12. A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus

/treatment Phase Type 1 Diabetes Mellitus Drug: BC Pram Ins Drug: Symlin® and Humulin® Drug: Humalog® Drug: Placebo Phase 1 Detailed Description: This is a single center, randomised, double-blind, active comparator controlled, three-period cross-over, single dose trial in subjects with type 1 diabetes mellitus. Each subject will be randomly allocated to a sequence of three treatments:(i) simultaneous administrations of BioChaperone® pramlintide human insulin (BC Pram Ins) and placebo, (ii) simultaneous (...) injections of pramlintide (Symlin®) and human insulin (Humulin®) and (iii) simultaneous injections of insulin lispro (Humalog®) and placebo. Subjects will come in a fasted state to the clinical trial centre in the morning, meal test procedures will be performed and subjects will stay at the clinical trial centre until the post-dose follow-up period has been terminated. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 24 participants

2018 Clinical Trials

13. The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas (DCLP3 Extension)

not to start any new non-insulin glucose-lowering agent during the course of the trial Exclusion Criteria Concurrent use of any non-insulin glucose-lowering agent other than metformin (including GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas). Hemophilia or any other bleeding disorder A condition, which in the opinion of the investigator or designee, would put the participant or study at risk Participation in another pharmaceutical or device trial at the time of enrollment

2018 Clinical Trials

14. Model Predictive Control (MPC) Artificial Pancreas vs. Sensor Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS) With Different Food Choices in the Outpatient Setting

to any form of nuts or ingredients present in the study meals (tomatoes etc). History of difficulty digesting food. Concurrent use of Afrezza or any non-insulin glucose-lowering agent other than metformin (including GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas). Hemophilia or any other bleeding disorder One or more episodes of hypoglycemia requiring an emergency room visit or hospitalization in the past 6 months. One or more episodes of hyperglycemia requiring

2018 Clinical Trials

15. A Pilot Test of t:Slim X2 With Control-IQ Technology

and not greater than 140 kg Exclusion Criteria: More than one episode of diabetic ketoacidosis (DKA) in the 6 months prior to enrollment More than one episode of severe hypoglycemia involving seizure or loss of consciousness in the 6 months prior to enrollment Concurrent use of any non-insulin glucose-lowering agent (including GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, biguanides, sulfonylureas and naturaceuticals). Hemophilia or any other bleeding disorder A condition, which in the opinion

2017 Clinical Trials

16. Feasibility Evaluation of an Artificial Pancreas With Glucose Prediction Trust Index

that would preclude wearing a CGM sensor or Pod. One or more seizures in the past year. Screening A1c ≥ 10% or serum creatinine ≥ 2.0 mg/dL. Any condition that could interfere with participating in the trial, based on investigator judgment. Concurrent use of any non-insulin glucose-lowering agent (including GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, biguanides, sulfonylureas and naturaceuticals), defined as using any of these medications within 30 days of the screening visit or during

2017 Clinical Trials

17. Disaggregation of Amylin Aggregate by Novel Conformationally Restricted Aminobenzoic Acid containing α/β and α/γ Hybrid Peptidomimetics (PubMed)

peptides for drug design against T2DM has been invigorated by recent FDA approval of Symlin, which is a large conformationally restricted peptide. However, Symlin still has some issues including solubility, oral bioavailability and cost of preparation. Herein, we introduced a novel strategy for conformationally restricted peptide design adopting a minimalistic approach for cost reduction. We have demonstrated efficient inhibition of amyloid formation of Amylin and its disruption by a novel class

Full Text available with Trip Pro

2017 Scientific reports

18. Amylin – Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity (PubMed)

metabolism relates to its satiating effect, but recent data indicate that amylin may also affect hedonic aspects in the control of eating, including a reduction of the rewarding value of food. Recently, several amylin-based peptides have been characterized. Pramlintide (Symlin®) is currently the only one being used clinically to treat type 1 and type 2 diabetes. However other amylin analogs with improved pharmacokinetic properties are being considered as anti-obesity treatment strategies. Several other

Full Text available with Trip Pro

2017 Molecular metabolism

19. PreDx® diabetes risk score (DRS)

, and thiazolidinediones are the most commonly prescribed medicines, and more recently, two Food and Drug Administration (FDA)- approved drugs (Symlin® and Byetta®; Amylin Pharmaceuticals Inc.) have entered the market. In addition to drug therapies to reduce T2D, nonpharmacological lifestyle and dietary interventions resulting in weight loss have resulted in reduction in incident T2D. To prevent diabetes, predicting disease development during a prediabetes stage may reduce the health and economic burden

2012 Health Technology Assessment (HTA) Database.

20. International Diabetes Closed Loop (iDCL) Trial: Research Site Training Protocol

(Humalog), insulin aspart (Novolog), or insulin glulisine (Apidra) Total daily insulin dose (TDD) less than 100 U/day Exclusion Criteria More than one episode of diabetic ketoacidosis (DKA) in the 6 months prior to enrollment More than one episode of severe hypoglycemia involving seizure of loss of consciousness in the 6 months prior to enrollment Medical need for chronic acetaminophen Concurrent use of any non-insulin glucose-lowering agent (including GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>